BridgeBio Pharma (2CL) Stock Statistics & Valuation Metrics
Total Valuation
BridgeBio Pharma has a market cap or net worth of EUR 13.07B. The enterprise value is EUR 15.72B.
- Market Cap
- EUR 13.07B
- Enterprise Value
- EUR 15.72B
Share Statistics
BridgeBio Pharma has 194,800,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 194,800,780
- Owned by Insiders
- 3.95%
- Owned by Institutions
- 40.55%
Financial Efficiency
BridgeBio Pharma’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is -108.46%.
- Return on Equity (ROE)
- 0.35
- Return on Assets (ROA)
- -0.78
- Return on Invested Capital (ROIC)
- -108.46%
- Return on Capital Employed (ROCE)
- -0.88
- Revenue Per Employee
- 501.58K
- Profits Per Employee
- -728.58K
- Employee Count
- 1,001
- Asset Turnover
- 0.54
- Inventory Turnover
- 1.06
Valuation Ratios
The current PE Ratio of BridgeBio Pharma is -24.65. BridgeBio Pharma’s PEG ratio is -0.74.
- PE Ratio
- -24.65
- PS Ratio
- 15.44
- PB Ratio
- -8.84
- Price to FCF
- -39.01
- Price to Operating Cash Flow
- -39.82
- PEG Ratio
- -0.74
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 502.08M and earned -729.31M in profits. Earnings per share was -3.79.
- Revenue
- 502.08M
- Gross Profit
- 473.81M
- Operating Income
- -569.09M
- Pretax Income
- -734.99M
- Net Income
- -729.31M
- EBITDA
- -676.45M
- Earnings Per Share (EPS)
- -3.79
Cash Flow
In the last 12 months, operating cash flow was -368.97M and capital expenditures -5.33M, giving a free cash flow of -374.31M billion.
- Operating Cash Flow
- -368.97M
- Free Cash Flow
- -374.31M
- Free Cash Flow per Share
- -1.91
Dividends & Yields
BridgeBio Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.56%
- Earnings Yield
- -3.88%
Stock Price Statistics
- Beta
- 0.59
- 52-Week Price Change
- 16.09%
- 50-Day Moving Average
- 61.61
- 200-Day Moving Average
- 62.55
- Relative Strength Index (RSI)
- 69.74
- Average Volume (3m)
- 145
Important Dates
BridgeBio Pharma upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
BridgeBio Pharma as a current ratio of 2.62, with Debt / Equity ratio of -131.40%
- Current Ratio
- 2.62
- Quick Ratio
- 2.52
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- -3.19
- Interest Coverage Ratio
- -10.72
Taxes
In the past 12 months, BridgeBio Pharma has paid 555.00K in taxes.
- Income Tax
- 555.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
BridgeBio Pharma EV to EBITDA ratio is -35.32, with an EV/FCF ratio of -41.57.
- EV to Sales
- 16.46
- EV to EBITDA
- -35.32
- EV to Free Cash Flow
- -41.57
- EV to Operating Cash Flow
- -42.17
Balance Sheet
BridgeBio Pharma has EUR 1.54B in cash and marketable securities with EUR 2.49B in debt, giving a net cash position of -EUR 955.19M billion.
- Cash & Marketable Securities
- EUR 1.54B
- Total Debt
- EUR 2.49B
- Net Cash
- -EUR 955.19M
- Net Cash Per Share
- -EUR 4.90
- Tangible Book Value Per Share
- -EUR 8.57
Margins
Gross margin is 93.51%, with operating margin of -43.35%, and net profit margin of -60.30%.
- Gross Margin
- 93.51%
- Operating Margin
- -43.35%
- Pretax Margin
- -61.23%
- Net Profit Margin
- -60.30%
- EBITDA Margin
- -46.60%
- EBIT Margin
- -47.10%
Analyst Forecast
The average price target for BridgeBio Pharma is EUR 98.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 98.21
- Price Target Upside
- 47.34% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 18
- Revenue Growth Forecast
- 157.05%
- EPS Growth Forecast
- 31.35%
Scores
- Smart Score
- 7
- AI Score
- ―
